Intrust Bank NA acquired a new position in shares of GlaxoSmithKline plc (NYSE:GSK) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 4,325 shares of the pharmaceutical company’s stock, valued at approximately $203,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Prime Capital Investment Advisors LLC bought a new position in shares of GlaxoSmithKline in the third quarter valued at approximately $26,000. Clear Harbor Asset Management LLC bought a new position in GlaxoSmithKline in the 4th quarter valued at approximately $29,000. Savior LLC bought a new position in GlaxoSmithKline in the 4th quarter valued at approximately $30,000. Vigilant Capital Management LLC bought a new position in GlaxoSmithKline in the 4th quarter valued at approximately $33,000. Finally, S.A. Mason LLC bought a new position in shares of GlaxoSmithKline during the fourth quarter valued at $38,000. Institutional investors own 11.49% of the company’s stock.
GSK has been the subject of a number of analyst reports. ValuEngine raised shares of GlaxoSmithKline from a “sell” rating to a “hold” rating in a research note on Thursday, February 6th. Shore Capital downgraded GlaxoSmithKline from a “hold” rating to a “sell” rating in a report on Wednesday, February 12th. UBS Group raised GlaxoSmithKline from a “neutral” rating to a “buy” rating in a research report on Wednesday, November 27th. Leerink Swann initiated coverage on shares of GlaxoSmithKline in a report on Monday, December 2nd. They set an “outperform” rating and a $53.00 target price on the stock. Finally, Barclays cut shares of GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a report on Thursday, January 16th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the stock. GlaxoSmithKline presently has an average rating of “Hold” and a consensus target price of $47.33.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 9th. Investors of record on Friday, February 21st will be given a dividend of $0.5994 per share. This represents a $2.40 dividend on an annualized basis and a yield of 5.61%. The ex-dividend date is Thursday, February 20th. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s dividend payout ratio (DPR) is 62.15%.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Read More: What is a dividend reinvestment plan?
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.